Congenital methaemoglobinaemia presenting in a 55-year-old man

Leila Izadi Firouzabadi, Paul Mead

DESCRIPTION

We present the case of a 55-year-old man admitted with influenza-like symptoms together with a non-productive cough. Past medical history was of renal failure of uncertain aetiology, kidney transplantation in 1998, thyroid cancer with thyroidec- tomy in 1999, cardiac ablation for atrial fibrillation in 2005 and sleep apnoea. On examination he was feverish at 38°C and centrally cyanosed (figure 1A, B). Oxygen saturation was 89% on 15 L of oxygen, blood gases revealed a PO2 of 36 together with a methaemoglobin of 15%. Chest X-ray was unremarkable. Initial treatment was with intravenous antibiotics, Tamiflu as well as intensive treatment unit transfer. Treatment of his methaemoglobinaemia was considered however for a number of reasons this was withheld including that he was taking a selective serotonin reuptake inhibitor, that he did not seem unduly distressed and that on further questioning he stated he had blue lips, tip of nose and fingertips for many years, raising the possibility of congenital methaemoglobinaemia. He later reported abdominal pain. CT of abdomen revealed a perforated duodenal ulcer with an associated complex fluid collection. Treatment was conservative with full recovery.

Investigation of this man’s methaemoglobinaemia revealed no recent history of taking any medications associated with acquired methaemoglobinaemia, haemoglobin electrophoresis was unremarkable and he did not have G6PDH deficiency. Subsequent enzyme testing showed that he had normal pyruvate kinase activity but was found to have low NADH-cytochrome b5 reductase activity confirming the diagnosis of congenital methaemoglobinaemia.

Congenital methaemoglobinaemia is a rare autosomal recessive condition which is due to cytochrome b5 reductase (Cyb5R) deficiency, deficiency of cytochrome b5 or haemoglobin M disease. Two types of Cyb5R reductase deficiency have been defined where type I is as a result of this enzyme deficiency in only erythrocytes and in type II, the enzyme is deficient in all tissues. While the symptoms are very mild in type I and the patients have a normal life expectancy, type II which is less common leads to a neurological dysfunction as well as a cyanosis and a significant reduced life span.

Patients with congenital disease develop physiological compensatory mechanisms such as erythrocytosis and can tolerate elevated levels of methaemoglobin (up to 40%) without symptoms. However, they may develop other symptoms such as shortness of breath and fatigue later in life due to age-related decline in cardiorespiratory physiology. Our patient has only recently developed shortness of breath having previously been an active participant in the transplant games for a number of years following his successful kidney transplant in 1998. No doubt this relates to age-related decline in cardiorespiratory reserve and additional comorbidities including the development of sleep apnoea. It is difficult to explain why his central cyanosis was not picked up earlier given his multiple comorbidities and medical variations. This may be due to factors such as been a mild genetic variant and that while suffering from renal failure, his cyanosis was less obvious due to anaemia resulting in a reduction of the absolute amount of methaemoglobin as this determines cyanosis rather than percentage alone. There is a chance of developing the significant symptoms if they have an exposure to oxidising agents. Our patient did not have a history of methaemoglobinaemia in his family.

Methylene blue is required in those who have the significant symptoms.

Learning points

- Central cyanosis as opposed to peripheral cyanosis is always pathological.
- Modern blood gas analysers detect methaemoglobin level.
- Duration of cyanosis and drug history are important in patients presenting with methaemoglobinaemia to distinguish congenital versus acquired disease.

To cite: Izadi Firouzabadi L, Mead P. BMJ Case Rep 2020;13:e236677. doi:10.1136/bcr-2020-236677
Provenance and peer review  Not commissioned; externally peer reviewed.

ORCID ID
Leila Izadi Firouzabadi http://orcid.org/0000-0001-5385-6273

REFERENCES